Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

LA Huppert, O Gumusay, D Idossa… - CA: a cancer journal for …, 2023 - Wiley Online Library
Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

[HTML][HTML] Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality

AJ Kerr, D Dodwell, P McGale, F Holt, F Duane… - Cancer treatment …, 2022 - Elsevier
Background Adjuvant and neoadjuvant breast cancer treatments can reduce breast cancer
mortality but may increase mortality from other causes. Information regarding treatment …

Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND …

OD Gentilini, E Botteri, C Sangalli, V Galimberti… - JAMA …, 2023 - jamanetwork.com
Importance Sentinel lymph node biopsy (SLNB) is the standard of care for axillary node
staging of patients with early breast cancer (BC), but its necessity can be questioned since …

Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology

WJ Gradishar, MS Moran, J Abraham… - Journal of the National …, 2024 - jnccn.org
Breast cancer is treated with a multidisciplinary approach involving surgical oncology,
radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in …

[HTML][HTML] Role of microbiota-derived short-chain fatty acids in cancer development and prevention

R Mirzaei, A Afaghi, S Babakhani, MR Sohrabi… - Biomedicine & …, 2021 - Elsevier
Following cancer, cells in a particular tissue can no longer respond to the factors involved in
controlling cell survival, differentiation, proliferation, and death. In recent years, it has been …

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

F Cardoso, S Kyriakides, S Ohno… - Annals of …, 2019 - annalsofoncology.org
In 2018, the predicted number of new breast cancers in 28 European Union (EU) countries
was 404 920, with estimated age-adjusted annual incidence of breast cancer of 144.9/100 …

Cancer progression and the invisible phase of metastatic colonization

CA Klein - Nature Reviews Cancer, 2020 - nature.com
Metastatic dissemination occurs very early in the malignant progression of a cancer but the
clinical manifestation of metastases often takes years. In recent decades, 5-year survival of …

Breast cancer treatment: a review

AG Waks, EP Winer - Jama, 2019 - jamanetwork.com
Importance Breast cancer will be diagnosed in 12% of women in the United States over the
course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed …

[HTML][HTML] 20-year risks of breast-cancer recurrence after stop** endocrine therapy at 5 years

H Pan, R Gray, J Braybrooke, C Davies… - … England Journal of …, 2017 - Mass Medical Soc
Background The administration of endocrine therapy for 5 years substantially reduces
recurrence rates during and after treatment in women with early-stage, estrogen-receptor …

Overcoming resistance to tumor-targeted and immune-targeted therapies

M Aldea, F Andre, A Marabelle, S Dogan, F Barlesi… - Cancer Discovery, 2021 - AACR
Resistance to anticancer therapies includes primary resistance, usually related to lack of
target dependency or presence of additional targets, and secondary resistance, mostly …